Vor Biopharma Inc. financial data

Symbol
VOR on Nasdaq
Location
100 Cambridgepark Drive, Suite 101, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 875 % -45%
Debt-to-equity 33.5 % +48.6%
Return On Equity -86.4 % -71.8%
Return On Assets -64.7 % -57.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 68.4M shares +1.27%
Common Stock, Shares, Outstanding 68.4M shares +1.37%
Entity Public Float 136M USD +17.7%
Common Stock, Value, Issued 7K USD 0%
Weighted Average Number of Shares Outstanding, Basic 68.3M shares +1.89%
Weighted Average Number of Shares Outstanding, Diluted 68.3M shares +1.89%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 94.6M USD +18.7%
General and Administrative Expense 30.2M USD -4.8%
Operating Income (Loss) -125M USD -12%
Nonoperating Income (Expense) 6.71M USD +26.3%
Net Income (Loss) Attributable to Parent -118M USD -11.3%
Earnings Per Share, Basic -1.73 USD/shares +14.4%
Earnings Per Share, Diluted -1.73 USD/shares +14.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 76.1M USD +136%
Marketable Securities, Current 9.86M USD -93.6%
Cash, Cash Equivalents, and Short-term Investments 85.9M USD
Other Assets, Current 272K USD -49.5%
Assets, Current 90.3M USD -52.8%
Property, Plant and Equipment, Net 8.29M USD -27.6%
Operating Lease, Right-of-Use Asset 37.6M USD -11.5%
Other Assets, Noncurrent 3.06M USD -6.27%
Assets 142M USD -43.6%
Accounts Payable, Current 2.01M USD +21.8%
Employee-related Liabilities, Current 3.41M USD +9.13%
Accrued Liabilities, Current 7.66M USD +5.51%
Liabilities, Current 13.8M USD +8.52%
Operating Lease, Liability, Noncurrent 29.7M USD -12.2%
Liabilities 43.5M USD -6.51%
Accumulated Other Comprehensive Income (Loss), Net of Tax -70K USD +83.9%
Retained Earnings (Accumulated Deficit) -399M USD -42.1%
Stockholders' Equity Attributable to Parent 98.1M USD -52%
Liabilities and Equity 142M USD -43.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -30.5M USD -25.5%
Net Cash Provided by (Used in) Financing Activities 96K USD -96.2%
Net Cash Provided by (Used in) Investing Activities 44M USD +577%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 68.4M shares +1.33%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 13.6M USD
Deferred Tax Assets, Valuation Allowance 104M USD +52.8%
Deferred Tax Assets, Gross 116M USD +44.9%
Operating Lease, Liability 33.8M USD -9.84%
Depreciation 3.6M USD +11.2%
Payments to Acquire Property, Plant, and Equipment 114K USD +21.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -118M USD -11.9%
Lessee, Operating Lease, Liability, to be Paid 46.8M USD -11.9%
Property, Plant and Equipment, Gross 18.2M USD +2.41%
Operating Lease, Liability, Current 4.11M USD +11.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 6.65M USD +1.11%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.59M USD +4.37%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 11.1M USD -21.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 6.68M USD +0.56%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 6.88M USD +3.01%
Operating Lease, Payments 1.64M USD +6.15%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 11.7M USD -0.6%
Share-based Payment Arrangement, Expense 10.9M USD -29.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%